Lepidoglyphus destructor extract. Determination of in vivo allergenic potency in histamine equivalent prick testing units (HEP).

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509541-13-00

Acronym

M603-STD-061

Enrollment

Registered

2024-08-14

Start date

2024-10-23

Completion date

Unknown

Last updated

2025-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergy to Lepidoglyphus destructor

Brief summary

To assess the concentration of Lepidoglyphus destructor extract that induces a wheal of size equivalent to that produced by a 10 mg/mL histamine dihydrochloride solution.

Interventions

DRUGPrick test of Lepidoglyphus destructor extract

DRUGSkin Prick Test Positive control

DRUGSkin Prick Test Negative control

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
To assess the concentration of Lepidoglyphus destructor extract that induces a wheal of size equivalent to that produced by a 10 mg/mL histamine dihydrochloride solution.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026